Abstract
The Human Cancer Models Initiative (HCMI) is reshaping cancer research by providing access to human relevant, patient‑derived advanced models with full clinical annotations and molecular characterization. This session will highlight advances in a subset of these models from pancreatic and intestinal cancers, including insights into redox metabolism during tumorigenesis, Ras‑driven signaling pathways, tumor–stroma cross‑talk, and biomarkers for early disease detection. We also highlight the critical role of these diverse cancer models in advancing precision oncology, demonstrating how genetic-, ethnic-, gender-, and age-representative patient‑derived organoids and functional modeling approaches can reveal tumor‑specific drug sensitivities and reduce health disparities. This session will also provide perspective on how ATCC, a non-profit standards organization, is facilitating global access to these HCMI models, addressing an urgent unmet need for standardized models within the new approach methodologies (NAM) framework.
*This Exhibitor Spotlight Theater was a promotional activity and was not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).
Download the presentation to explore the critical role of patient-derived cancer models in advancing oncology
DownloadPresenters
Carolina Lucchesi, PhD, Principal Scientist, Head of Microphysiological Systems, ATCC
Claudia K. Petritsch, PhD, Associate Professor in Research, Director Pediatric Cancer Model Development Center, Sr. Scientist in Neuroscience, Stanford University
Benjamin David Hopkins, PhD, Assistant Professor of Research in Systems and Computational Biomedicine, Weill Cornell Medical College
Human Cancer Models Initiative
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.
ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Find next-generation models
